Kiniksa Pharmaceuticals International, plc KNSA

75.08 (0.26) (0.35%) as of 25 Sep
Market cap
$5.9B
P/E
70.2×
Growth Flags show if company had growth for consecutive years

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Revenue 677.56 423.24 270.26 220.18 38.54 — — — — —
Revenue Growth 60.09% 56.60% 22.74% 471.24% — — — — — —
Cost of Revenue 77.67 60.91 33.41 22.90 9.10 3.81 3.28 0.29 0.03 0.02
Gross Profit 599.89 362.33 236.85 197.29 29.44 (3.80) (3.28) (0.29) (0.03) (0.02)
R&D Expenses 96.85 111.62 76.10 65.49 99.30 112.04 135.00 86.60 56.36 17.44
SG&A Expenses 196.27 168.01 129.43 97.95 85.95 45.32 34.96 21.56 9.04 6.56
Operating Income 77.22 (45.62) (25.20) 9.77 (156.64) (157.36) (169.96) (108.16) (65.40) (24.00)
Non-operating Income/Expense 11.65 9.46 8.54 1.25 0.10 1.13 6.05 4.72 0.53 0.07
EBT 88.87 (36.15) (16.65) 11.03 (156.54) (156.23) (163.91) (103.44) (64.87) (23.94)
Income Tax Provision 29.86 7.04 (30.74) (172.34) 1.39 5.15 (2.05) (0.21) 0.00 0.04
Income after Tax 59.01 (43.19) 14.08 183.36 (157.92) (161.38) (161.87) (103.23) (64.87) (23.97)
Net Income Common 59.01 (43.19) 14.08 183.36 (157.92) (161.38) (161.87) (103.23) (64.87) (23.97)
EPS (Basic) 0.80 (0.60) 0.20 2.64 (2.30) (2.61) (2.99) (3.49) (35.84) (91.61)
EPS (Diluted) 0.75 (0.60) 0.20 2.60 (2.30) (2.61) (2.99) (3.49) (35.84) (91.61)
Shares (Basic, Weighted) 74.20 71.42 70.06 69.38 68.58 61.84 54.05 29.55 1.81 0.26
Shares (Diluted, Weighted) 78.98 71.42 71.92 70.42 68.58 61.84 54.05 29.55 1.81 0.26
Gross Margin 88.54% 85.61% 87.64% 89.60% 76.39% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin 11.40% (10.78%) (9.32%) 4.44% (406.38%) 0.00% 0.00% 0.00% 0.00% 0.00%
EBT margin 13.12% (8.54%) (6.16%) 5.01% (406.13%) 0.00% 0.00% 0.00% 0.00% 0.00%
Net Profit Margin 8.71% (10.21%) 5.21% 83.28% (409.72%) 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Margin 20.13% 6.01% 4.87% 2.63% (380.64%) 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA 78.78 (43.92) (22.85) 12.18 (154.28) (154.96) (167.89) (107.87) (65.37) (23.98)
EBIT 77.22 (45.62) (25.20) 9.77 (156.64) (157.36) (169.96) (108.16) (65.40) (24.00)
Income from Continuous Operations 59.01 (43.19) 14.08 183.36 (157.92) (161.38) (161.87) (103.23) (64.87) (23.97)
Consolidated Net Income/Loss 59.01 (43.19) 14.08 183.36 (157.92) (161.38) (161.87) (103.23) (64.87) (23.97)
EPS (Basic, from Continuous Ops) 0.80 (0.60) 0.20 2.64 (2.30) (2.61) (2.99) (3.49) (35.84) (91.61)
EPS (Basic, Consolidated) 0.80 (0.60) 0.20 2.64 (2.30) (2.61) (2.99) (3.49) (35.84) (91.61)
EPS (Diluted, from Cont. Ops) 0.75 (0.60) 0.20 2.60 (2.30) (2.61) (2.99) (3.49) (35.84) (91.61)
Shares (Diluted, Average) 78.98 71.42 71.92 70.42 68.58 61.84 54.05 29.55 — —
EPS (Diluted, Consolidated) 0.75 (0.60) 0.20 2.60 (2.30) (2.61) (2.99) (3.49) (35.84) (91.61)
EBITDA Margin 11.63% (10.38%) (8.46%) 5.53% (400.27%) 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Margin 20.36% 6.07% 4.92% 2.64% (327.67%) 0.00% 0.00% 0.00% 0.00% 0.00%

Fold the line items

In millions of $ except per-share values · columns are period end dates